Quote:“We are encouraged…”
Quote:“These findings give us additional insight into how leronlimab may be interacting with the biology of metastatic colorectal cancer while maintaining a favorable tolerability...
Yeah, getting real tired of the soft-peddling in our PRs.
What’s that? Leronlimab “may be” interacting with the cancer?
Oh, really, based on all the incredible data thus far, you’re just “encouraged”…? And all that safety data is “favorable tolerability”…?
JFC. No wonder the sp is .25
Where’s the “Everyone at CytoDyn and our partner Natera is really excited by these results and can’t wait to share more of the incredible data we’re seeing at ASMO in January”...?